Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Deliang Fu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0009-0005-6224-6879; OpenAlex author ID A5041657955. Sources: OpenAlex.

Their work

Papers
61 (first author 0, last author 28)
Trials
0
Grants
0
Labs led
1
Collaborators
188
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 3 papers · 2014: 4 papers · 2015: 2 papers · 2016: 5 papers · 2017: 5 papers · 2018: 6 papers · 2019: 6 papers · 2020: 6 papers · 2021: 6 papers · 2022: 9 papers · 2023: 2 papers · 2024: 4 papers · 2025: 1 paper

Papers 50 of 61

  1. Ionizable cationic lipid nanoparticles loaded with miRNA-125b/BLZ945 for pancreatic cancer treatment. Last author DOI 10.1002/bab.2701↗
  2. Integrating plasma protein-centric multi-omics to identify potential therapeutic targets for pancreatic cancer. Co-author DOI 10.1186/s12967-024-05363-9↗
  3. Ubiquitin-specific protease 7 maintains c-Myc stability to support pancreatic cancer glycolysis and tumor growth. Co-author DOI 10.1186/s12967-024-05962-6↗
  4. Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial. Co-author DOI 10.3892/ol.2024.14293↗
  5. Recurrence scoring system predicting early recurrence for patients with pancreatic ductal adenocarcinoma undergoing pancreatectomy and portomesenteric vein res… Last author DOI 10.4240/wjgs.v16.i10.3185↗
  6. Single-cell mapping reveals several immune subsets associated with liver metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.medj.2023.07.010↗
  7. Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer. Co-author DOI 10.1200/jco.22.02630↗
  8. Characterization of DNA damage response deficiency in pancreatic cancer patients from China. Co-author DOI 10.1002/cac2.12238↗
  9. Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2022.103897↗
  10. Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer. Co-author DOI 10.1016/j.jncc.2022.08.006↗
  11. Exosome-delivered CD44v6/C1QBP complex drives pancreatic cancer liver metastasis by promoting fibrotic liver microenvironment. Co-author DOI 10.1136/gutjnl-2020-323014↗
  12. The expression and survival significance of sodium glucose transporters in pancreatic cancer. Co-author DOI 10.1186/s12885-021-09060-4↗
  13. The Intricate Crosstalk Between Insulin and Pancreatic Ductal Adenocarcinoma: A Review From Clinical to Molecular. Last author DOI 10.3389/fcell.2022.844028↗
  14. Gemcitabine-Loaded Albumin Nanoparticle Exerts An Antitumor Effect on Gemcitabine-Resistant Pancreatic Cancer Cells Induced by MDR1 and MRP1 Overexpression in … Co-author DOI 10.3389/fsurg.2022.890412↗
  15. CDCA8/SNAI2 Complex Activates CD44 to Promote Proliferation and Invasion of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers14215434↗
  16. Identification of Genes Associated with Liver Metastasis in Pancreatic Cancer Reveals PCSK6 as a Crucial Mediator. Co-author DOI 10.3390/cancers15010241↗
  17. Basal microvilli define the metabolic capacity and lethal phenotype of pancreatic cancer. Last author DOI 10.1002/path.5588↗
  18. Label-Free Histology and Evaluation of Human Pancreatic Cancer with Coherent Nonlinear Optical Microscopy. Co-author DOI 10.1021/acs.analchem.1c03861↗
  19. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Co-author DOI 10.1038/s41392-021-00659-4↗
  20. Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response. Co-author DOI 10.1038/s41421-021-00271-4↗
  21. The Expression and Survival Significance of Glucose Transporter-1 in Pancreatic Cancer: Meta-Analysis, Bioinformatics Analysis and Retrospective Study. Co-author DOI 10.1080/07357907.2021.1950755↗
  22. Liver-Metastasis-Related Genes are Potential Biomarkers for Predicting the Clinical Outcomes of Patients with Pancreatic Adenocarcinoma. Last author DOI 10.3389/pore.2021.1609822↗
  23. Controlling Nutritional Status score is superior to Prognostic Nutritional Index score in predicting survival and complications in pancreatic ductal adenocarci… Last author DOI 10.1017/s0007114520002299↗
  24. Insulin-like growth factor 1-induced enolase 2 deacetylation by HDAC3 promotes metastasis of pancreatic cancer. Co-author DOI 10.1038/s41392-020-0146-6↗
  25. WD repeat-containing protein 1 maintains β-Catenin activity to promote pancreatic cancer aggressiveness. Last author DOI 10.1038/s41416-020-0929-0↗
  26. Single-nucleotide polymorphisms based genetic risk score in the prediction of pancreatic cancer risk. Co-author DOI 10.3748/wjg.v26.i22.3076↗
  27. Partial pancreatic tail preserving subtotal pancreatectomy for pancreatic cancer: Improving glycemic control and quality of life without compromising oncologic… Last author DOI 10.4240/wjgs.v12.i12.491↗
  28. Blood-based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Pancreatic Cancer and its Value to Guide Clinical Treatment. Last author DOI 10.7150/jca.43087↗
  29. High cytoplasm HABP1 expression as a predictor of poor survival and late tumor stage in pancreatic ductal adenocarcinoma patients. Last author DOI 10.1016/j.ejso.2018.09.020↗
  30. LRG-1 promotes pancreatic cancer growth and metastasis via modulation of the EGFR/p38 signaling. Last author DOI 10.1186/s13046-019-1088-0↗
  31. A Comprehensive Proteome Analysis of Peripheral Blood Mononuclear Cells (PBMCs) to Identify Candidate Biomarkers of Pancreatic Cancer. Last author DOI 10.21873/cgp.20114↗
  32. A Long Non-coding RNA Signature to Improve Prognostic Prediction of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2019.01160↗
  33. Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges. Co-author DOI 10.3748/wjg.v25.i23.2839↗
  34. Pancreatoduodenectomy with portal vein resection favors the survival time of patients with pancreatic ductal adenocarcinoma: A propensity score matching analys… Last author DOI 10.3892/ol.2019.10822↗
  35. The roles of ID-1 in human pancreatic ductal adenocarcinoma and the therapeutic effects of 2-methoxyestradiol. Last author DOI 10.1093/carcin/bgy035↗
  36. Stroma - A Double-Edged Sword in Pancreatic Cancer: A Lesson From Targeting Stroma in Pancreatic Cancer With Hedgehog Signaling Inhibitors. Co-author DOI 10.1097/mpa.0000000000001023↗
  37. Genome-Wide Analysis Identified a Number of Dysregulated Long Noncoding RNA (lncRNA) in Human Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1177/1533034617748429↗
  38. Tumor-Infiltrating Platelets Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6727-8↗
  39. Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression. Co-author DOI 10.2147/ijn.s166769↗
  40. Dynamic quantitative detection of ABC transporter family promoter methylation by MS-HRM for predicting MDR in pancreatic cancer. Co-author DOI 10.3892/ol.2018.8041↗
  41. Complement component 1, q subcomponent binding protein (C1QBP) in lipid rafts mediates hepatic metastasis of pancreatic cancer by regulating IGF-1/IGF-1R signa… Last author DOI 10.1002/ijc.30831↗
  42. Magnetic mesoporous nanospheres anchored with LyP-1 as an efficient pancreatic cancer probe. Co-author DOI 10.1016/j.biomaterials.2016.11.006↗
  43. An evaluation study of reported pancreatic adenocarcinoma risk-associated SNPs from genome-wide association studies in Chinese population. Co-author DOI 10.1016/j.pan.2017.09.009↗
  44. Portal vein resection and reconstruction with artificial blood vessels is safe and feasible for pancreatic ductal adenocarcinoma patients with portal vein invo… Last author DOI 10.18632/oncotarget.20847↗
  45. Combination of preoperative CEA and CA19-9 improves prediction outcomes in patients with resectable pancreatic adenocarcinoma: results from a large follow-up c… Co-author DOI 10.2147/ott.s116136↗
  46. Process of hepatic metastasis from pancreatic cancer: biology with clinical significance. Last author DOI 10.1007/s00432-015-2024-0↗
  47. Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.humpath.2016.05.002↗
  48. Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability. Last author DOI 10.3748/wjg.v22.i45.10024↗
  49. The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreati… Co-author DOI 10.3892/ijo.2015.3316↗
  50. Circulating tumor cells in pancreatic cancer patients: efficacy in diagnosis and value in prognosis. Last author PMID 27755967↗

Closest collaborators

The 25 strongest of 188 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chen Jin · 23 shared papers, 2013–2024 · strength 2.49
  2. Jichun Gu · 14 shared papers, 2017–2024 · strength 1.92
  3. Ji Li · 12 shared papers, 2013–2024 · strength 1.53
  4. Lie Yao · 16 shared papers, 2013–2024 · strength 1.42
  5. Feng Yang · 14 shared papers, 2012–2024 · strength 1.17
  6. Yishen Mao · 8 shared papers, 2018–2024 · strength 1.05
  7. Hengchao Li · 7 shared papers, 2017–2024 · strength 0.94
  8. Zhibo Xie · 7 shared papers, 2016–2022 · strength 0.80
  9. Junyuan Deng · 5 shared papers, 2021–2022 · strength 0.76
  10. Lei Kong · 5 shared papers, 2021–2022 · strength 0.76
  11. Jiali Du · 5 shared papers, 2021–2022 · strength 0.76
  12. Yongjian Jiang · 10 shared papers, 2013–2024 · strength 0.76
  13. Hang He · 8 shared papers, 2013–2024 · strength 0.74
  14. Ji Li · 7 shared papers, 2014–2024 · strength 0.69
  15. Baian Tao · 3 shared papers, 2022–2024 · strength 0.52
  16. Di Yang · 9 shared papers, 2011–2020 · strength 0.49
  17. Yongwei Sun · 6 shared papers, 2015–2022 · strength 0.49
  18. Yifan Zhang · 4 shared papers, 2017–2022 · strength 0.46
  19. Feng Jiao · 4 shared papers, 2021–2022 · strength 0.41
  20. Jiujie Cui · 4 shared papers, 2021–2022 · strength 0.41
  21. Qiongzhu Dong · 4 shared papers, 2019–2023 · strength 0.41
  22. Yan Zheng · 4 shared papers, 2019–2023 · strength 0.41
  23. Christiane J. Bruns · 4 shared papers, 2019–2023 · strength 0.41
  24. Yue Zhao · 4 shared papers, 2019–2023 · strength 0.41
  25. Beiyuan Hu · 3 shared papers, 2020–2023 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.